Here are the 10-Q quarterly reports from Enveric Biosciences, Inc. (ENVB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences, Inc. is a pre-revenue biotechnology company developing next-generation, small-molecule neuroplastogenic therapeutics, led by EB-003 in the EVM301 Series for psychiatric and neurological disorders. EB-003 advanced through IND-enabling preclinical work, including positive phototoxicity analysis and initiation of GLP-compliant genotoxicity studies.
For the six months ended June 30, 2026, the company reported a net loss of $4,661,206 and total operating expenses of $4,660,611, with no revenue. Cash was $8,296,296 and working capital $7,931,850, bolstered by $8,348,207 of net financing cash inflows from private placements, ATM sales, and warrant exercises, raising shareholders’ equity to $8,082,524.
Management states there is substantial doubt about the ability to continue as a going concern over the next year without additional capital. Internal controls over financial reporting remain ineffective due to previously identified material weaknesses. As of August 12, 2026, 4,475,884 common shares were outstanding.
Enveric Biosciences reported a net loss of $1.63M for the three months ended March 31, 2026, as it continues preclinical development of lead candidate EB-003 for mental health disorders. Operating expenses fell to $1.63M from $2.19M a year earlier, driven by lower R&D and G&A costs.
The company ended the quarter with $4.91M in cash and working capital of $4.91M, after raising $2.50M through a registered direct offering, concurrent private placement, and at-the-market (ATM) share sales. In April 2026 it added about $4.5M of net proceeds from another private placement and additional warrant exercises.
Despite these financings, Enveric has an accumulated deficit of $116.48M, negative operating cash flow of $2.26M in the quarter, and discloses that these factors raise substantial doubt about its ability to continue as a going concern over the next year. Management plans further capital raises and disciplined spending while advancing EB-003 toward IND-enabling studies.